Cargando…

Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study

BACKGROUND: Interferon (IFN) alpha conjugation to polyethylene glycol (PEG) results in a better pharmacokinetic profile and efficacy. The aim of this study was to compare the pharmacokinetic, pharmacodynamic and safety properties of a new, locally developed, 40-kDa PEG-IFN alpha-2b preparation with...

Descripción completa

Detalles Bibliográficos
Autores principales:	García-García, Idrian, González-Delgado, Carlos A, Valenzuela-Silva, Carmen M, Díaz-Machado, Alina, Cruz-Díaz, Marisol, Nodarse-Cuní, Hugo, Pérez-Pérez, Orlando, Bermúdez-Badell, Cimara H, Ferrero-Bibilonia, Joel, Páez-Meireles, Rolando, Bello-Rivero, Iraldo, Castro-Odio, Fidel R, López-Saura, Pedro A
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3001701/ https://www.ncbi.nlm.nih.gov/pubmed/21092287 http://dx.doi.org/10.1186/1471-2210-10-15

Ejemplares similares

Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers
por: Costa, Marisa Boff, et al.
Publicado: (2018)

Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteers
por: García-García, Idrian, et al.
Publicado: (2016)

Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study
por: Anasagasti-Angulo, Lorenzo, et al.
Publicado: (2009)

Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG®) in patients with mycosis fungoides: an open-label trial
por: García-Vega, Yanelda, et al.
Publicado: (2012)

Interferon-lambda 3 and 4 Polymorphisms Increase Sustained Virological Responses and Regulate Innate Immunity in Antiviral Therapy With Pegylated Interferon-Alpha
por: da Silva, Andréa Marques Vieira, et al.
Publicado: (2021)

Adjuvant interferon gamma in patients with pulmonary atypical Mycobacteriosis: A randomized, double-blind, placebo-controlled study
por: Milanés-Virelles, María T, et al.
Publicado: (2008)

Adjuvant interferon gamma in patients with drug – resistant pulmonary tuberculosis: a pilot study
por: Suárez-Méndez, Roberto, et al.
Publicado: (2004)

Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase
por: Modi, Tapasvi, et al.
Publicado: (2021)

Evaluation of methodologies to determine the effect of specific active immunotherapy on VEGF levels in phase I clinical trial patients with advanced solid tumors
por: Sánchez Ramírez, Javier, et al.
Publicado: (2018)

Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors
por: Wu, Huali, et al.
Publicado: (2015)

Influence of Surface-Modification via PEGylation or Chitosanization of Lipidic Nanocarriers on In Vivo Pharmacokinetic/Pharmacodynamic Profiles of Apixaban
por: Zaky, Mohamed F., et al.
Publicado: (2023)

Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma
por: Daud, A. I., et al.
Publicado: (2010)

Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum]
Publicado: (2019)

Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria
por: Qi, Yulan, et al.
Publicado: (2021)

Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: A parallel, randomized, double blind study
por: Pérez-Oliva, Jorge F, et al.
Publicado: (2005)

Construction, purification, and characterization of a chimeric TH1 antagonist
por: Bello-Rivero, Iraldo, et al.
Publicado: (2006)

Pharmacokinetics/Pharmacodynamics and tolerability of cefiderocol in the clinical setting
por: Perea, José Ramón Azanza, et al.
Publicado: (2022)

Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants
por: Sánchez Ramírez, Javier, et al.
Publicado: (2017)

Genetic PEGylation
por: Tada, Seiichi, et al.
Publicado: (2012)

Piggybacked by PEGylation?
por: Shin, Kichul
Publicado: (2018)

Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children
por: Hou, Ling, et al.
Publicado: (2015)

Ice Cream: new virtual reality tool for the assessment of executive functions in children and adolescents: a normative study
por: Fernandez, Manuel Antonio, et al.
Publicado: (2023)

Study of GABA in Healthy Volunteers: Pharmacokinetics and Pharmacodynamics
por: Li, Junfeng, et al.
Publicado: (2015)

Can pegylated interferon improve the outcome of polycythemia vera patients?
por: Crisà, Elena, et al.
Publicado: (2017)

The pharmacokinetic and pharmacodynamic properties and short-term outcome of a novel once-weekly PEGylated recombinant human growth hormone for children with growth hormone deficiency
por: Liang, Yan, et al.
Publicado: (2022)

PEGylated versus non-PEGylated magnetic nanoparticles as camptothecin delivery system
por: Castillo, Paula M, et al.
Publicado: (2014)

Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses
por: Serra López-Matencio, Jose M., et al.
Publicado: (2021)

Pharmacokinetic–Pharmacodynamic Modeling of Midazolam in Pediatric Surgery
por: Flores-Pérez, Carmen, et al.
Publicado: (2023)

Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation
por: Milano, G, et al.
Publicado: (2004)

Pharmacokinetics and pharmacodynamics of an orally disintegrating tablet formulation of dexlansoprazole
por: Kukulka, Michael, et al.
Publicado: (2016)

The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers
por: Umemura, Kazuo, et al.
Publicado: (2016)

Formulation and PEGylation optimization of the therapeutic PEGylated phenylalanine ammonia lyase for the treatment of phenylketonuria
por: Bell, Sean M., et al.
Publicado: (2017)

Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study
por: Gil-Gil, Miguel J., et al.
Publicado: (2021)

Enhanced MRI T(2) Relaxivity in Contrast-Probed Anchor-Free PEGylated Iron Oxide Nanoparticles
por: Thapa, Bibek, et al.
Publicado: (2017)

Synthesis of gamma radiation-induced PEGylated cisplatin for cancer treatment
por: González Torres, Maykel, et al.
Publicado: (2018)

Use of Protein Pegylation to Prolong the Antiviral Effect of IFN Against FMDV
por: Diaz-San Segundo, Fayna, et al.
Publicado: (2021)

Granjas acuáticas modernas /
por: García-Badell, José Javier
Publicado: (2009)

Cálculo de las acciones sísmicas : programa informático con múltiples ejemplos de cálculo
por: García-Badell, José Javier
Publicado: (2006)

Cálculo de la energía solar /
por: García-Badell, José Javier
Publicado: (2003)

Clipper 5.0 : guía del compilador para DBase III+ y DBase IV /
por: García-Badell, José Javier
Publicado: (1992)

Cannot write session to /tmp/vufind_sessions/sess_lku1gvl2ql1ivgjv9u33v8g02a